ReviewInternational journal of hematology2026
Beyond nuclear export: chromatin-bound XPO1/CRM1 as a transcriptional scaffold.
Review in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
XPO1/CRM1 (also known as Exportin-1) is best known as a RanGTP-dependent nuclear export receptor and has been explored as a therapeutic target in various diseases, including acute myeloid leukemia (AML). Emerging evidence, however, indicates that XPO1 is also detectable on chromatin at active regulatory regions, including the HOX clusters and the MEIS1 locus-key transcriptional nodes in multiple AML subtypes. Recent studies support a "pre-bound XPO1 platform" model in which genetically diverse leukemia drivers, such as nucleoporin (NUP98/NUP214) fusions and mutant NPM1 (NPM1c), are recruited to these loci via phenylalanine-glycine (FG) repeat-XPO1 or nuclear export signal (NES)-XPO1 interactions, coupled with partner-encoded chromatin contacts. This dual engagement may stabilize locus-restricted assemblies and lower the threshold for liquid-liquid phase separation (LLPS)-linked condensate formation that sustains aberrant HOX/MEIS-driven transcriptional programs. By reframing XPO1 from a nuclear export receptor to a chromatin-associated interaction hub, this perspective provides a framework for understanding transcriptionally addicted AML subtypes and highlights opportunities to selectively target chromatin-associated XPO1 functions in HOX/MEIS-driven AML.
Indexed as
Identifiers
42565971What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.